Joëlle Goetz

Joëlle Goetz

Auto-generated profile, based on publicly available information

Joëlle Goetz

Oral Medicine, Oral Oncology, and Dentistry, Miami Cancer Institute, Baptist Health South Florida, Miami, FL; Now with Oral Medicine, College of Dental Medicine, Yeshiva University, New York, NY

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2024 in Journal of Dental Research
Verified
Journal Article
Closed access
JGJ.W. Goetz
J.W. Goetz
GRG. Rabinowits
G. Rabinowits
NKN. Kalman
N. Kalman
AVA. Villa
A. Villa
The introduction of immune checkpoint inhibitors (ICIs) to oncological care has transformed the management of various malignancies, including head and neck squamous cell carcinoma (HNSCC), offering improved outcomes. The first-line treatment of recurrent and malignant HNSCC for many years was combined platinum, 5-fluorouracil, and cetuximab. Recently, the ICI pembrolizumab was approved as a first-line treatment, with or without chemotherapy, based on tumor and immune cell percentage of programmed-death ligand 1 (PD-L1). Multiple head and neck (HN) cancer trials have subsequently explored immunotherapies in combination with surgery, chemotherapy, and/or radiation. Immunotherapy regimens may be personalized by tumor biomarker, including PD-L1 content, tumor mutational burden, and microsatellite instability. However, further clinical trials are needed to refine biomarker-driven protocols and standardize pathological methods to guide combined regimen timing, sequencing, and deescalation. Gaps remain for protocols using immunotherapy to reverse oral premalignant lesions, particularly high-risk leukoplakias. A phase II nonrandomized controlled trial, using the ICI nivolumab, showed a 2-y cancer-free survival of 73%, although larger trials are needed. Guidelines are also needed to standardize the role of dental evaluation and care before, during, and after immunotherapy, specifically in regard to oral immune-related adverse events and their impact on cancer recurrence. Standardized diagnostic and oral care coordination strategies to close these gaps are needed to ensure continued success of HN cancer immunotherapy.

13 October 2009 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
LSLaëtitia Sparsa
Laëtitia Sparsa
NANaji Afif
Naji Afif
JGJoëlle Goetz
Joëlle Goetz
CSChristelle Sordet
Christelle Sordet
ECEmmanuel Chatelus
Emmanuel Chatelus
JSJean Sibilia
Jean Sibilia

1 July 2016 in Revue Francophone des Laboratoires
Verified
Journal Article
Closed access
JGJoëlle Goetz
Joëlle Goetz
BNBenoit Nespola
Benoit Nespola
JSJean Sibilia
Jean Sibilia

8 January 2026 in The Journal of the American Dental Association
Verified
Journal Article
Closed access
LFLeonardo Finotello
Leonardo Finotello
JGJeffrey Goetz
Jeffrey Goetz
UFUzma Farooq
Uzma Farooq
AVAlessandro Villa
Alessandro Villa